8 August 2016 ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2016
5 July 2016 Oryzon nominates ORY-3001, a specific LSD1 inhibitor, next drug candidate to enter preclinical development in non-oncological indications
4 April 2016 ORYZON Announces First Subject Dosed in Phase I Healthy Volunteer Study Evaluating Oral Epigenetic drug ORY-2001 for Alzheimer’s Disease